GIM
EBS icon

Glenmede Investment Management’s Emergent Biosolutions EBS Stock Holding History

Glenmede Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$183K Buy
20,798
+5,597
+37% +$43.5K ﹤0.01% 1275
2025
Q2 		$97K Buy
+15,201
New +$87K ﹤0.01% 1307

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
OHA
Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Glenmede Investment Management's EBS Position: Q3 2025 in Review

Glenmede Investment Management increased its Emergent Biosolutions (EBS) stake by 37% in Q3 2025, buying an estimated $43.5K and bringing the position to 20,798 shares worth $183K. The position accounts for ﹤0.01% of the portfolio, ranked #1275.

Glenmede Investment Management first reported a position in EBS in Q2 2025 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold EBS as of Q3 2025.

  • Glenmede Investment Management held 20,798 shares of Emergent Biosolutions worth $183K as of Q3 2025.
  • Glenmede Investment Management bought 5,597 Emergent Biosolutions shares in Q3 2025, an estimated $43.5K.
  • Emergent Biosolutions made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1275 holding.
  • Glenmede Investment Management first reported a position in Emergent Biosolutions in Q2 2025 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.